Shares of iBio, Inc. (NYSEMKT:IBIO – Get Free Report) were down 9% on Wednesday . The company traded as low as $2.32 and last traded at $2.32. Approximately 188,341 shares traded hands during mid-day trading, an increase of 66% from the average daily volume of 113,212 shares. The stock had previously closed at $2.55.
iBio Stock Performance
The business has a fifty day simple moving average of $2.38 and a two-hundred day simple moving average of $2.19. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.04.
iBio Company Profile
iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.
See Also
- Five stocks we like better than iBio
- What Are Dividends? Buy the Best Dividend Stocks
- Rocket Lab is the Right Stock for the Right Time
- What Do S&P 500 Stocks Tell Investors About the Market?
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- How to Invest in the Best Canadian Stocks
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
